Evidence map›Paper›PMID 30832755›Full record

ArticleOncology research2019

Nutlin-3-Induced Sensitization of Non-Small Cell Lung Cancer Stem Cells to Axitinib-Induced Apoptosis Through Repression of Akt1/Wnt Signaling.

Meng Wang, Xin Wang, Yuan Li, Qiang Xiao, Xiao-Hai Cui, Guo-Dong Xiao, Ji-Chang Wang, Chong-Wen Xu, Hong Ren, Dapeng Liu

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Itraconazole Alters the Stem Cell Characteristics of A549 and NCI-H460 Human Lung Cancer Cells by Suppressing Wnt Signaling.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Meng WangDepartment of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Xin WangDepartment of Gastroenterology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Yuan LiSchool of Humanities and Social Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Qiang XiaoDepartment of Medical Oncology, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Xiao-Hai CuiDepartment of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Guo-Dong XiaoDepartment of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Ji-Chang WangDepartment of Vascular and Endovascular Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Chong-Wen XuDepartment of Otorhinolaryngology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Hong RenDepartment of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
Dapeng LiuDepartment of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, P.R. China.
First Affiliated Hospital of Xi'an Jiaotong University · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the potential biological activities of nutlin-3 in the regulation of growth and proliferation of non-small cell lung cancer (NSCLC) stem cells (CSCs), which may help in sensitizing to axitinib-induced apoptosis. Nutlin-3 induction of p53 expression was used to test its role in controlling the cell division pattern and apoptosis of NSCLC cells. A549 cells and H460 cells were pretreated with nutlin-3 and then treated with either an Akt1 activator or shRNA-GSK3β, to investigate the potential role of p53 sensitization in the biological effects of axitinib. We also determined the expression levels of GSK3β and p-Akt1 in patients with NSCLC and determined their potential association with survival data using Kaplan-Meier plots and CBIOTAL. Increased p53 expression stimulated the induction of apoptosis by axitinib and promoted asymmetric cell division (ACD) of NSCLC CSCs. The repression of Akt phosphorylation induced by nutlin-3 promoted the ACD of lung CSCs, decreasing the proportion of the stem cell population. In addition to the induction of apoptosis by axitinib through inhibition of Wnt signaling, nutlin-3 treatment further enhanced axitinib-induced apoptosis by inhibiting Akt1/GSK3β/Wnt signaling. The low expression of GSK3β and increased expression of p-Akt in patients with NSCLC were closely associated with the development of NSCLC. TP53 stimulates the induction of apoptosis in NSCLC by axitinib and the ACD of lung CSCs through its regulatory effects on the p53/Akt/GSK3β pathways.

Indexed as

A549 CellsAntineoplastic Combined Chemotherapy ProtocolsApoptosisAxitinibCarcinoma, Non-Small-Cell LungCell ProliferationDrug SynergismHumansImidazolesImmunohistochemistryLung NeoplasmsPiperazinesProto-Oncogene Proteins c-aktWnt Signaling PathwayAKT1 protein, humanAxitinibImidazolesnutlin 3PiperazinesProto-Oncogene Proteins c-akt

Identifiers

PMID30832755
PMCPMC7848271
OpenAlexW2918410203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.